Skip to main content
Login
Contact
Subscribe
Search form
Search
The Evening Leader?
Home
Forms
News
Sports
Classifieds
Place a Classified Ad
Classified Display Ads
Service Directory
Obituaries
Entertainment
Local Guide
Special Sections
Talking About...
Photos
Videos
Games
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Urogen Pharma Ltd Ordinary Shares
(NQ:
URGN
)
41.93
USD
-0.33 (-0.78%)
Official Closing Price
/ Updated:
3:59 PM EDT, Oct 19, 2018
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
46,600
Open
42.42
Bid (Size)
41.93 (5)
Ask (Size)
42.01 (1)
Prev. Close
42.26
Today's Range
40.70 - 43.13
52wk Range
25.56 - 69.57
Shares Outstanding
4,473,373
Dividend Yield
N/A
Performance
YTD
+8.51%
+8.51%
1 Month
-13.99%
-13.99%
3 Month
-11.43%
-11.43%
6 Month
-27.03%
-27.03%
1 Year
+53.70%
+53.70%
Top News
More News
UroGen Pharma Reports Second Quarter 2018 Financial Results and Recent Corporate Developments
August 14, 2018
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...
Read More
from
GlobeNewswire News Releases
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer
August 08, 2018
UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company today announced that Peter P. Pfreundschuh has been appointed as Chief Financial Officer (CFO) effective August 20, 2018....
Read More
from
GlobeNewswire News Releases
More News
Read More
UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018
from
Business Wire News Releases
UroGen Pharma to Report Second Quarter 2018 Financial Results on Tuesday, August 14, 2018
August 07, 2018
from
GlobeNewswire News Releases
Jones “Woody” Bryan Joins UroGen Pharma as Senior Vice President of Business Development
September 11, 2018
from
Business Wire News Releases
UroGen Pharma Submits Investigational New Drug (IND) Application for UGN-102 (VesiGel™) for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC)
July 11, 2018
from
GlobeNewswire News Releases
UroGen Pharma Appoints Shawn Cline Tomasello to its Board of Directors
July 10, 2018
from
GlobeNewswire News Releases
UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award
June 13, 2018
from
GlobeNewswire News Releases
Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and CoStar Group — Discovering Underlying Factors of Influence
June 06, 2018
from
GlobeNewswire News Releases
UroGen Pharma Announces Stephen Mullennix as Interim Chief Financial Officer and Jason Patel as Vice President of Finance
June 05, 2018
from
GlobeNewswire News Releases
UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference
May 29, 2018
from
GlobeNewswire News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
X
Username
*
Password
*
Request new password
